C4d antibody | 10-11
Mouse anti Human C4d
Mouse anti Human C4d antibody, clone 10-11 recognizes complement component 4d. The presence of C4d in renal peritubular capillaries is a key indicator for acute antibody-mediated rejection. C4d is a footprint of complement activation, making it a perfect maker of allograft rejection.
- Product Type
- Monoclonal Antibody
|Product Code||Applications||Datasheet||MSDS||Pack Size||List Price||Quantity|
|2222-8004||C E IF P* WB||0.1 mg|
C4d was accepted in 2003 into the Banff classification for identification of acute AMR (Racusen et al. 2003). Mouse anti Human C4d antibody, clone 10-11 is specific for C4d, a marker that can be used in the detection of acute AMR for kidney, heart, pancreas and lung allografts. C4d is regarded as a key marker of antibody-mediated cell injury and humoral rejection (Sacks and Chowdhury 2002).
Complement 1 complex cleaves complement 4 (C4) to form C4b and C4a. C4b levels are strictly regulated. Single site cleavage of the C4b’s alpha chain by Factor I forms iC4b and blocks C3 convertase, inhibiting opsonization and activation of the classical pathway. This requires C4 binding protein or CR1 as a cofactor. iC4b is further degraded into C4d and C4c. C4b’s short half life means that C4d is present in serum at high enough concentrations to make it a useful marker for classical complement activation (Collins et al. 1999).
Mouse anti Human C4d antibody, clone 10-11 is used to detect the biomarker C4d which has been described as a “footprint” of antibody mediated tissue rejection (Sacks and Chowdhury 2002). The internal thioester of C4b becomes exposed during cleavage to C4d and forms a covalent bond with the cell surface. The longer half-life of covalently bound C4d makes it a footprint of complement activation long after weakly bound antibodies have been cleared by the blood stream (Sacks and Chowdhury 2002).
C4 has also been linked to susceptibility to systemic lupus erythematosus (Yang et al. 2004) and rheumatoid arthritis (Makinde et al. 1989).
- Target Species
- Species Cross-Reactivity
Target Species Cross Reactivity Mouse Dog Bovine Cat Rabbit Rat Guinea Pig Sheep
- N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Borate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide (NaN3)
- Native, from human plasma
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted.
Avoid repeated freezing and thawing as this may denature the antibody.
Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
- P0C0L4 Related reagents
- P0C0L5 Related reagents
- Entrez Gene
- C4A Related reagents
- C4B Related reagents
- For research purposes only
Applications of C4d antibody
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen||1/100||1/750|
|Immunohistology - Paraffin 1|
- 1It has been reported that this antibody works very well on acetone-fixed, frozen renal biopsies. Strong staining is observed in the glomeruli and in some cases the peritubular capillaries.
Clone 10-11 has given variable results on formalin-fixed, paraffin-embedded sections. It has been observed that pre-treatment with 88% formic acid for 20 minutes at room temperature is beneficial (6).
For best results Bio-Rad recommend HISTAR detection kits (STAR3000A/B/C).
Secondary Antibodies Available
Product Specific References
References for C4d antibody
Mauiyyedi, S. et al. (2002) Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification.
J Am Soc Nephrol. 13 (3): 779-87.
Collins, A.B. et al. (1999) Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries.
J Am Soc Nephrol. 10 (10): 2208-14.
Knechtle, S.J. et al. (2003) Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.
Am J Transplant. 3 (6): 722-30.
Mauiyyedi, S. et al. (2001) Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries.
J Am Soc Nephrol. 12 (3): 574-82.
Rogers, J. et al. (1992) Complement activation by beta-amyloid in Alzheimer disease.
Proc Natl Acad Sci U S A. 89 (21): 10016-20.
Troxell, M.L. et al. (2010) Pancreas allograft rejection: analysis of concurrent renal allograft biopsies and posttherapy follow-up biopsies.
Transplantation. 90: 75-84.
Rowe, P. et al. (2013) Increased complement activation in human type 1 diabetes pancreata.
Diabetes Care. 36 (11): 3815-7.
Johnson, R.K. et al. (2013) Acute tubular injury is an important component in type I acute antibody-mediated rejection.
Transplant Proc. 45: 3262-8.
Roden, A.C. et al. (2016) Transbronchial Cryobiopsies in the Evaluation of Lung Allografts: Do the Benefits Outweigh the Risks?
Arch Pathol Lab Med. 140 (4): 303-11.
Verghese, P.S. et al. (2016) The clinical implications of the unique glomerular complement deposition pattern in transplant glomerulopathy.
J Nephrol. Nov 15. [Epub ahead of print]
Troxell, M.L. & Lanciault, C. (2016) Practical Applications in Immunohistochemistry: Evaluation of Rejection and Infection in Organ Transplantation.
Arch Pathol Lab Med. 140 (9): 910-25.
Jain, D. et al. (2017) Detection of T and B cells specific complement-fixing alloantibodies using flow cytometry: A diagnostic approach for a resource limited laboratory.
Asian J Transfus Sci. 11 (2): 171-9.
Dugum, M. et al. (2014) Re-examination of sinusoidal deposition of complement 4d in liver allografts: experience from a single institution.
Int J Clin Exp Pathol. 7 (2): 784-91.
Sánchez-escuredo, A. et al. (2016) Borderline rejection in ABO-incompatible kidney transplantation.
Clin Transplant. 30 (8): 872-9.
Stoltzner, S.E. et al. (2000) Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.
Am J Pathol. 156 (2): 489-99.
Sacks, S.H. & Chowdhury, P. (2002) Footprints of humoral rejection.
Curr Opin Nephrol Hypertens. 11 (6): 627-8.
Racusen, L.C. et al. (2003) Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.
Am J Transplant. 3 (6): 708-14.
Yang, Y. et al. (2004) The intricate role of complement component C4 in human systemic lupus erythematosus.
Curr Dir Autoimmun. 7: 98-132.
Makinde, V.A. et al. (1989) Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.
Ann Rheum Dis. 48 (4): 302-6.